October 3, 2006 -- Biogen Idec will pay over $200 million Iincluding milestones) to UCB in an MS collaboration; Spectrum and AEterna Zentaris reported positive Phase II results for ozarelix, a BPH drug; Beckman Coulter will pay $185 million for Lumigen, a diagnostics company; Cytokinetics reported cancer drug ispinesib failed a Phase II trial; EpiCept filed to begin a Phase I test of its cancer drug, EPC2407; Impax Labs and McNeil-PPC settled their suit over a generic version of ADHD drug Concerta; Xoma will humanize a monoclonal antibody for cancer; and Curis and Micromet have settled their financial differences. The Centient Biotech 200™ closed with a two point gain at 3792.32, a rise of .05%. More details...
